Christopher Gabrieli Christopher Gabrieli Christopher Gabrieli

Christopher Gabrieli

Chris Gabrieli, a partner in Bessemer's Cambridge, Mass. office, joined the firm in 1986 to launch its healthcare practice. In 25 years of investing with Bessemer, he has invested broadly in healthcare and other industries. He currently focuses on biotechnology,  healthcare services and education.

Chris is closely involved in Bessemer’s investments in cancer-therapeutics firm AVEO Pharmaceuticals and biopharmaceutical firms Acceleron Pharma, Proteon, Oxagen and Transave.  He serves on the board of digital textbook pioneer Flat World Knowledge.

Among his past portfolio companies are biopharmaceutical company Affymax ( NASDAQ: AFFY); electronic health-record solutions company Allscripts (NASDAQ:MDRX); Isis Pharmaceuticals, a company that is the leading innovator in RNA-targeting pharmaceuticals; PerSeptive BioSystems, a maker of instruments for protein synthesis (acquired by Perkin-Elmer); Sirtris Pharmaceuticals, a developer of small-molecule drugs (NASDAQ: SIRT, acquired by GlaxoSmithKline); TravCorps, a pioneering healthcare-staffing company acquired by Cross Country Healthcare (CCRN); and VistaCare (NASDAQ:VSTA), a provider of hospice-care services.

Prior to his career at Bessemer, Chris founded and served as CEO of GMIS, a healthcare-software company he co-founded and helped build, take public and sell to the leading industry consolidator, McKesson (NYSE: MCK). Bessemer was an investor in GMIS.

Chris graduated from Harvard University with a B.A. in history and science and completed two years of the Columbia College of Physicians & Surgeons M.D. program. He is also a leader in education innovation and is founder and chairman of the National Center on Time & Learning and a lecturer at the Harvard Graduate School of Education.